FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Hans Pannekoek

Research Profile

Chemicals & Drugs

Anatomy

Concepts & Ideas

Living Beings

Mouse

Genes & Molecular Sequences

Amino Acid Sequences

Co-author Network

Publications

TOP 3
Bianca C W Groenendijk; Germaine F J D Benus; Anita Klous; Yolanda M Pacheco; Oscar L Volger; Joost O Fledderus; Valerie Ferreira; Marten A Engelse; Hans Pannekoek; Peter ten Dijke; Anton J G Horrevoets; Carlie J M de Vries
Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-β.
Thijs W H Pols; Peter I Bonta; Nuno M M Pires; Iker Otermin; Mariska Vos; Margreet R De Vries; Marco van Eijk; Jeroen Roelofsen; Louis M Havekes; Paul H A Quax; André B P van Kuilenburg; Vivian de Waard; Hans Pannekoek; Carlie J M de Vries
6-mercaptopurine inhibits atherosclerosis in apolipoprotein e*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages.
Peter I Bonta; Hanke L Matlung; Mariska Vos; Stephan L M Peters; Hans Pannekoek; Erik N T P Bakker; Carlie J M de Vries
Nuclear receptor Nur77 inhibits vascular outward remodelling and reduces macrophage accumulation and matrix metalloproteinase levels.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Hans Pannekoek (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Bianca C W Groenendijk; Germaine F J D Benus; Anita Klous; Yolanda M Pacheco; Oscar L Volger; Joost O Fledderus; Valerie Ferreira; Marten A Engelse; Hans Pannekoek; Peter ten Dijke; Anton J G Horrevoets; Carlie J M de Vries
Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-β.
Experimental cell research 2011;317(2):131-42.
2010: Thijs W H Pols; Peter I Bonta; Nuno M M Pires; Iker Otermin; Mariska Vos; Margreet R De Vries; Marco van Eijk; Jeroen Roelofsen; Louis M Havekes; Paul H A Quax; André B P van Kuilenburg; Vivian de Waard; Hans Pannekoek; Carlie J M de Vries
6-mercaptopurine inhibits atherosclerosis in apolipoprotein e*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages.
Arteriosclerosis, thrombosis, and vascular biology 2010;30(8):1591-7.
2010: Peter I Bonta; Hanke L Matlung; Mariska Vos; Stephan L M Peters; Hans Pannekoek; Erik N T P Bakker; Carlie J M de Vries
Nuclear receptor Nur77 inhibits vascular outward remodelling and reduces macrophage accumulation and matrix metalloproteinase levels.
Cardiovascular research 2010;87(3):561-8.
2010: Peter I Bonta; Thijs W H Pols; Claudia M van Tiel; Mariska Vos; E Karin Arkenbout; Jakub Rohlena; Karel T Koch; Moniek P M de Maat; Michael W T Tanck; Robbert J de Winter; Hans Pannekoek; Erik A L Biessen; Ilze Bot; Carlie J M de Vries
Nuclear receptor Nurr1 is expressed in and is associated with human restenosis and inhibits vascular lesion formation in mice involving inhibition of smooth muscle cell proliferation and inflammation.
Circulation 2010;121(18):2023-32.
2009: Claudia M van Tiel; Peter I Bonta; Saskia Z H Rittersma; Marcel A M Beijk; Edward J Bradley; Anita M Klous; Karel T Koch; Frank Baas; J Wouter Jukema; Douwe Pons; M Lourdes Sampietro; Hans Pannekoek; Robbert J De Winter; Carlie J M de Vries
p27kip1-838C>A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity.
Circulation 2009;120(8):669-76.
2008: Joost O Fledderus; Reinier A Boon; Oscar L Volger; Hanna Hurttila; Seppo Ylä-Herttuala; Hans Pannekoek; Anna-Liisa Levonen; Anton J G Horrevoets
KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(7):1339-46.
2008: Thijs W H Pols; Roelof Ottenhoff; Mariska Vos; Johannes Levels; Paul H A Quax; Joost C M Meijers; Hans Pannekoek; Albert K Groen; Carlie J M de Vries
Nur77 modulates hepatic lipid metabolism through suppression of SREBP1c activity.
Biochemical and biophysical research communications 2008;366(4):910-6.
2007: Oscar L Volger; Joost O Fledderus; Natasja Kisters; Ruud D Fontijn; Perry Moerland; Johan Kuiper; Theo Van berkel; Ann-Pascale J J Bijnens; Mat J A P Daemen; Hans Pannekoek; Anton J G Horrevoets
Distinctive expression of chemokines and transforming growth factor-beta signaling in human arterial endothelium during atherosclerosis.
The American journal of pathology 2007;171(1):326-37.
2007: Valerie Ferreira; Ko Willems van Dijk; Albert K Groen; Rogier M Vos; Jos van der Kaa; Marion J J Gijbels; Louis M Havekes; Hans Pannekoek
Macrophage-specific inhibition of NF-kappaB activation reduces foam-cell formation.
Atherosclerosis 2007;192(2):283-90.
2007: Joost O Fledderus; Johannes V van Thienen; Reinier A Boon; Rob J Dekker; Jakub Rohlena; Oscar L Volger; Ann-Pascale J J Bijnens; Mat J A P Daemen; Johan Kuiper; Theo Van berkel; Hans Pannekoek; Anton J G Horrevoets
Prolonged shear stress and KLF2 suppress constitutive proinflammatory transcription through inhibition of ATF2.
Blood 2007;109(10):4249-57.
2007: Reinier A Boon; Joost O Fledderus; Oscar L Volger; Eva J A van Wanrooij; Evangelia Pardali; Frank Weesie; Johan Kuiper; Hans Pannekoek; Peter ten Dijke; Anton J G Horrevoets
KLF2 suppresses TGF-beta signaling in endothelium through induction of Smad7 and inhibition of AP-1.
Arteriosclerosis, thrombosis, and vascular biology 2007;27(3):532-9.
2007: Nuno M M Pires; Thijs W H Pols; Margreet R De Vries; Claudia M van Tiel; Peter I Bonta; Mariska Vos; E Karin Arkenbout; Hans Pannekoek; J Wouter Jukema; Paul H A Quax; Carlie J M de Vries
Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation.
Circulation 2007;115(4):493-500.
2006: Richard R Sprenger; Ruud D Fontijn; Jan van Marle; Hans Pannekoek; Anton J G Horrevoets
Spatial segregation of transport and signalling functions between human endothelial caveolae and lipid raft proteomes.
The Biochemical journal 2006;400(3):401-10.
2006: Ruud D Fontijn; Jakub Rohlena; Jan van Marle; Hans Pannekoek; Anton J G Horrevoets
Limited contribution of claudin-5-dependent tight junction strands to endothelial barrier function.
European journal of cell biology 2006;85(11):1131-44.
2006: Johannes V van Thienen; Joost O Fledderus; Rob J Dekker; Jakub Rohlena; Gerben A van Ijzendoorn; Neeltje Kootstra; Hans Pannekoek; Anton J G Horrevoets
Shear stress sustains atheroprotective endothelial KLF2 expression more potently than statins through mRNA stabilization.
Cardiovascular research 2006;72(2):231-40.
2006: Peter I Bonta; Claudia M van Tiel; Mariska Vos; Thijs W H Pols; Johannes V van Thienen; Valerie Ferreira; E Karin Arkenbout; Jurgen Seppen; C Arnold Spek; Tom van der Poll; Hans Pannekoek; Carlie J M de Vries
Nuclear receptors Nur77, Nurr1, and NOR-1 expressed in atherosclerotic lesion macrophages reduce lipid loading and inflammatory responses.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(10):2288-94.
2006: Vivian de Waard; E Karin Arkenbout; Mariska Vos; Astrid I M Mocking; Hans W M Niessen; Wim Stooker; Bas A J M de Mol; Paul H A Quax; Erik N T P Bakker; Ed VanBavel; Hans Pannekoek; Carlie J M de Vries
TR3 nuclear orphan receptor prevents cyclic stretch-induced proliferation of venous smooth muscle cells.
The American journal of pathology 2006;168(6):2027-35.
2006: Rob J Dekker; Reinier A Boon; Mariska G Rondaij; Astrid Kragt; Oscar L Volger; Yvonne W Elderkamp; Joost C M Meijers; Jan Voorberg; Hans Pannekoek; Anton J G Horrevoets
KLF2 provokes a gene expression pattern that establishes functional quiescent differentiation of the endothelium.
Blood 2006;107(11):4354-63.
2006: Vivian de Waard; Hjalmar R Hansen; Henri H M Spronk; Janneke J Timmerman; Hans Pannekoek; Sandrine Florquin; Pieter H Reitsma; Hugo ten Cate
Differential expression of tissue factor mRNA and protein expression in murine sepsis. The role of the granulocyte revisited.
Thrombosis and haemostasis 2006;95(2):348-53.
2006: Mirella C L G Gouverneur; Jos A E Spaan; Hans Pannekoek; Ruud D Fontijn; Hans Vink
Fluid shear stress stimulates incorporation of hyaluronan into endothelial cell glycocalyx.
American journal of physiology. Heart and circulatory physiology 2006;290(1):H458-2.
2005: Rob J Dekker; Johannes V van Thienen; Jakub Rohlena; Saskia C A de Jager; Yvonne W Elderkamp; Jurgen Seppen; Carlie J M de Vries; Erik A L Biessen; Theo Van berkel; Hans Pannekoek; Anton J G Horrevoets
Endothelial KLF2 links local arterial shear stress levels to the expression of vascular tone-regulating genes.
The American journal of pathology 2005;167(2):609-18.
2004: Richard R Sprenger; Dave Speijer; Jaap Willem Back; Chris G de Koster; Hans Pannekoek; Anton J G Horrevoets
Comparative proteomics of human endothelial cell caveolae and rafts using two-dimensional gel electrophoresis and mass spectrometry.
Electrophoresis 2004;25(1):156-72.
2003: Marten A Engelse; E Karin Arkenbout; Hans Pannekoek; Carlie J M de Vries
Activin and TR3 orphan receptor: two 'atheroprotective' genes as evidenced in dedicated mouse models.
Clinical and experimental pharmacology & physiology 2003;30(11):894-9.
2003: Nicholas J Beauchamp; Tanja A E Van Achterberg; Marten A Engelse; Hans Pannekoek; Carlie J M de Vries
Gene expression profiling of resting and activated vascular smooth muscle cells by serial analysis of gene expression and clustering analysis.
Genomics 2003;82(3):288-99.
2003: E Karin Arkenbout; Maaike van Bragt; Eric Eldering; Chris van Bree; Jos M Grimbergen; Paul H A Quax; Hans Pannekoek; Carlie J M de Vries
TR3 orphan receptor is expressed in vascular endothelial cells and mediates cell cycle arrest.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(9):1535-40.
2003: Rob J Dekker; Hans Pannekoek; Anton J G Horrevoets
A steady-state competition model describes the modulating effects of thrombomodulin on thrombin inhibition by plasminogen activator inhibitor-1 in the absence and presence of vitronectin.
European journal of biochemistry / FEBS 2003;270(9):1942-51.
2003: E Karin Arkenbout; Rob J Dekker; Carlie J M de Vries; Anton J G Horrevoets; Hans Pannekoek
Focusing on transcription factor families in atherogenesis: the function of LKLF and TR3.
Thrombosis and haemostasis 2003;89(3):522-9.
2003: Vivian de Waard; Tanja A E Van Achterberg; Nicholas J Beauchamp; Hans Pannekoek; Carlie J M de Vries
Cardiac ankyrin repeat protein (CARP) expression in human and murine atherosclerotic lesions: activin induces CARP in smooth muscle cells.
Arteriosclerosis, thrombosis, and vascular biology 2003;23(1):64-8.
2002: Vivian de Waard; E Karin Arkenbout; Peter Carmeliet; Volkhard Lindner; Hans Pannekoek
Plasminogen activator inhibitor 1 and vitronectin protect against stenosis in a murine carotid artery ligation model.
Arteriosclerosis, thrombosis, and vascular biology 2002;22(12):1978-83.
2002: Tom J M Molenaar; Chantal C M Appeldoorn; Sonja A M de Haas; Ingrid N Michon; Arnaud Bonnefoy; Marc F Hoylaerts; Hans Pannekoek; Theo Van berkel; Johan Kuiper; Erik A L Biessen
Specific inhibition of P-selectin-mediated cell adhesion by phage display-derived peptide antagonists.
Blood 2002;100(10):3570-7.
2002: E Karin Arkenbout; Vivian de Waard; Maaike van Bragt; Tanja A E Van Achterberg; Jos M Grimbergen; Bruno Pichon; Hans Pannekoek; Carlie J M de Vries
Protective function of transcription factor TR3 orphan receptor in atherogenesis: decreased lesion formation in carotid artery ligation model in TR3 transgenic mice.
Circulation 2002;106(12):1530-5.
2002: Rob J Dekker; Simone van Soest; Ruud D Fontijn; Sonia Salamanca; Philip G de Groot; Ed VanBavel; Hans Pannekoek; Anton J G Horrevoets
Prolonged fluid shear stress induces a distinct set of endothelial cell genes, most specifically lung Krüppel-like factor (KLF2).
Blood 2002;100(5):1689-98.
2002: Marten A Engelse; JanWillem H P Lardenoye; Jolanda M Neele; Jos M Grimbergen; Margreet R De Vries; Martine L M Lamfers; Hans Pannekoek; Paul H A Quax; Carlie J M de Vries
Adenoviral activin a expression prevents intimal hyperplasia in human and murine blood vessels by maintaining the contractile smooth muscle cell phenotype.
Circulation research 2002;90(10):1128-34.
2002: Onno C Leeksma; Tanja A E Van Achterberg; Yoshikazu Tsumura; Junko Toshima; Eric Eldering; Wilma G M Kroes; Clemens Mellink; Marcel Spaargaren; Kensaku Mizuno; Hans Pannekoek; Carlie J M de Vries
Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1.
European journal of biochemistry / FEBS 2002;269(10):2546-56.
2002: Houshang Monajemi; Ruud D Fontijn; Hans Pannekoek; Anton J G Horrevoets
The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue.
Genomics 2002;79(4):539-46.
2001: Marten A Engelse; Jolanda M Neele; Antonius L J J Bronckers; Hans Pannekoek; Carlie J M de Vries
Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix gla protein in human atherogenesis.
Cardiovascular research 2001;52(2):281-9.
2001: Houshang Monajemi; E Karin Arkenbout; Hans Pannekoek
Gene expression in atherogenesis.
Thrombosis and haemostasis 2001;86(1):404-12.
2001: Ruud D Fontijn; Bruno Goud; Arnaud Echard; Florence Jollivet; Jan van Marle; Hans Pannekoek; Anton J G Horrevoets
The human kinesin-like protein RB6K is under tight cell cycle control and is essential for cytokinesis.
Molecular and cellular biology 2001;21(8):2944-55.
2001: AA Stoop; Eric Eldering; Timothy R Dafforn; Randy J Read; Hans Pannekoek
Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
Journal of molecular biology 2001;305(4):773-83.
2000: JG Neels; BM van den Berg; Koen Mertens; H ter Maat; Hans Pannekoek; Anton-Jan van Zonneveld; Peter J Lenting
Activation of factor IX zymogen results in exposure of a binding site for low-density lipoprotein receptor-related protein.
Blood 2000;96(10):3459-65.
2000: AA Stoop; L Jespers; Ignace Lasters; Eric Eldering; Hans Pannekoek
High-density mutagenesis by combined DNA shuffling and phage display to assign essential amino acid residues in protein-protein interactions: application to study structure-function of plasminogen activation inhibitor 1 (PAI-I).
Journal of molecular biology 2000;301(5):1135-47.
2000: Carlie J M de Vries; Tanja A E Van Achterberg; Anton J G Horrevoets; JW ten Cate; Hans Pannekoek
Differential display identification of 40 genes with altered expression in activated human smooth muscle cells. Local expression in atherosclerotic lesions of smags, smooth muscle activation-specific genes.
The Journal of biological chemistry 2000;275(31):23939-47.
2000: C Hop; A Guilliatt; M Daly; Hubert P J C de Leeuw; Herm-Jan Brinkman; Ian R Peake; Jan A van Mourik; Hans Pannekoek
Assembly of multimeric von Willebrand factor directs sorting of P-selectin.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(7):1763-8.
2000: AA Stoop; Florea Lupu; Hans Pannekoek
Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(4):1143-9.
1999: Marten A Engelse; Jolanda M Neele; Tanja A E Van Achterberg; Benien E van Aken; Ron van Schaik; Hans Pannekoek; Carlie J M de Vries
Human activin-A is expressed in the atherosclerotic lesion and promotes the contractile phenotype of smooth muscle cells.
Circulation research 1999;85(10):931-9.
1999: Rob J Dekker; A Eichinger; AA Stoop; W Bode; Hans Pannekoek; Anton J G Horrevoets
The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
Journal of molecular biology 1999;293(3):613-27.
1999: JG Neels; BM van den Berg; Aivar Lookene; Gunilla Olivecrona; Hans Pannekoek; Anton-Jan van Zonneveld
The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties.
The Journal of biological chemistry 1999;274(44):31305-11.
1999: Peter J Lenting; JG Neels; BM van den Berg; P P Clijsters; D W Meijerman; Hans Pannekoek; Jan A van Mourik; Koen Mertens; Anton-Jan van Zonneveld
The light chain of factor VIII comprises a binding site for low density lipoprotein receptor-related protein.
The Journal of biological chemistry 1999;274(34):23734-9.
1999: Anton J G Horrevoets; Ruud D Fontijn; Anton-Jan van Zonneveld; Carlie J M de Vries; JW ten Cate; Hans Pannekoek
Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes.
Blood 1999;93(10):3418-31.
1999: Vivian de Waard; BM van den Berg; J Veken; R Schultz-Heienbrok; Hans Pannekoek; Anton-Jan van Zonneveld
Serial analysis of gene expression to assess the endothelial cell response to an atherogenic stimulus.
Gene 1999;226(1):1-8.
1998: Ivo R Horn; BM van den Berg; Søren K Moestrup; Hans Pannekoek; Anton-Jan van Zonneveld
Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
Thrombosis and haemostasis 1998;80(5):822-8.
1998: Henrik Gårdsvoll; Anton-Jan van Zonneveld; Arne Holm; Eric Eldering; M van Meijer; Keld Danø; Hans Pannekoek
Selection of peptides that bind to plasminogen activator inhibitor 1 (PAI-1) using random peptide phage-display libraries.
FEBS letters 1998;431(2):170-4.
1997: M van Meijer; Age K Smilde; G Tans; Michael E Nesheim; Hans Pannekoek; Anton J G Horrevoets
The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin.
Blood 1997;90(5):1874-82.
1997: Philip W Friederich; Marcel Levi; Bart J Biemond; Peter A Charlton; D Templeton; Anton-Jan van Zonneveld; PB Bevan; Hans Pannekoek; JW ten Cate
Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces postthrombolysis thrombus growth in rabbits.
Circulation 1997;96(3):916-21.
1997: Ivo R Horn; BM van den Berg; P Z van der Meijden; Hans Pannekoek; Anton-Jan van Zonneveld
Molecular analysis of ligand binding to the second cluster of complement-type repeats of the low density lipoprotein receptor-related protein. Evidence for an allosteric component in receptor-associated protein-mediated inhibition of ligand binding.
The Journal of biological chemistry 1997;272(21):13608-13.
1997: C Hop; Vivian de Waard; Jan A van Mourik; Hans Pannekoek
Lack of gradual regulation of tetracycline-controlled gene expression by the tetracyclin-repressor/VP16 transactivator (tTA) in cultured cells.
FEBS letters 1997;405(2):167-71.
1997: M van Meijer; AA Stoop; Age K Smilde; K T Preissner; Anton-Jan van Zonneveld; Hans Pannekoek
The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator.
Thrombosis and haemostasis 1997;77(3):516-21.
1997: A Stoop; M van Meijer; Anton J G Horrevoets; Hans Pannekoek
Molecular advances in plasminogen activator inhibitor 1 interaction with thrombin and tissue-type plasminogen activator.
Trends in cardiovascular medicine 1997;7(2):47-51.
1997: C Hop; Ruud D Fontijn; Jan A van Mourik; Hans Pannekoek
Polarity of constitutive and regulated von Willebrand factor secretion by transfected MDCK-II cells.
Experimental cell research 1997;230(2):352-61.
1997: Anton J G Horrevoets; Hans Pannekoek; Michael E Nesheim
A steady-state template model that describes the kinetics of fibrin-stimulated [Glu1]- and [Lys78]plasminogen activation by native tissue-type plasminogen activator and variants that lack either the finger or kringle-2 domain.
The Journal of biological chemistry 1997;272(4):2183-91.
1997: Anton J G Horrevoets; Hans Pannekoek; Michael E Nesheim
Production and characterization of recombinant human plasminogen(S741C-fluorescein). A novel approach to study zymogen activation without generation of active protease.
The Journal of biological chemistry 1997;272(4):2176-82.
1996: M van Meijer; Y Roelofs; JG Neels; Anton J G Horrevoets; Anton-Jan van Zonneveld; Hans Pannekoek
Selective screening of a large phage display library of plasminogen activator inhibitor 1 mutants to localize interaction sites with either thrombin or the variable region 1 of tissue-type plasminogen activator.
The Journal of biological chemistry 1996;271(13):7423-8.
1995: Anton-Jan van Zonneveld; BM van den Berg; M van Meijer; Hans Pannekoek
Identification of functional interaction sites on proteins using bacteriophage-displayed random epitope libraries.
Gene 1995;167(1-2):49-52.
1995: Anton J G Horrevoets; Age K Smilde; J C Fredenburgh; Hans Pannekoek; Michael E Nesheim
The activation-resistant conformation of recombinant human plasminogen is stabilized by basic residues in the amino-terminal hinge region.
The Journal of biological chemistry 1995;270(26):15770-6.
1995: I R Horn; Søren K Moestrup; BM van den Berg; Hans Pannekoek; Morten S Nielsen; Anton-Jan van Zonneveld
Analysis of the binding of pro-urokinase and urokinase-plasminogen activator inhibitor-1 complex to the low density lipoprotein receptor-related protein using a Fab fragment selected from a phage-displayed Fab library.
The Journal of biological chemistry 1995;270(20):11770-5.
1995: H A Stringer; Hans Pannekoek
The significance of fibrin binding by plasminogen activator inhibitor 1 for the mechanism of tissue-type plasminogen activator-mediated fibrinolysis.
The Journal of biological chemistry 1995;270(19):11205-8.
1995: Bart J Biemond; Marcel Levi; Ruben Coronel; Michiel J Janse; JW ten Cate; Hans Pannekoek
Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
Circulation 1995;91(4):1175-81.
1995: Hans Pannekoek; M van Meijer; H Gaardsvoll; Anton-Jan van Zonneveld
Functional display of proteins, mutant proteins, fragments of proteins and peptides on the surface of filamentous (bacterio) phages: A review.
Cytotechnology 1995;18(1-2):107-12.
1995: R Fontijn; C Hop; H J Brinkman; R Slater; A Westerveld; Jan A van Mourik; Hans Pannekoek
Maintenance of vascular endothelial cell-specific properties after immortalization with an amphotrophic replication-deficient retrovirus containing human papilloma virus 16 E6/E7 DNA.
Experimental cell research 1995;216(1):199-207.
1994: H A Stringer; P van Swieten; Anton J G Horrevoets; Age K Smilde; Hans Pannekoek
The role of the finger domain of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in initiation and progression of thrombolysis.
Thrombosis and haemostasis 1994;72(6):900-5.
1994: M van Meijer; R K Gebbink; Klaus T Preissner; Hans Pannekoek
Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1).
FEBS letters 1994;352(3):342-6.
1994: H A Stringer; P van Swieten; H F Heijnen; J J Sixma; Hans Pannekoek
Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler loop.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1994;14(9):1452-8.
1994: Guido Tans; Gerry A F Nicolaes; M Christella L G D Thomassen; Coenraad Hemker; Anton-Jan van Zonneveld; Hans Pannekoek; Jan Rosing
Activation of human factor V by meizothrombin.
The Journal of biological chemistry 1994;269(23):15969-72.
1994: Anton J G Horrevoets; Age K Smilde; C de Vries; Hans Pannekoek
The specific roles of finger and kringle 2 domains of tissue-type plasminogen activator during in vitro fibrinolysis.
The Journal of biological chemistry 1994;269(17):12639-44.
1993: Hans Pannekoek; M van Meijer; R R Schleef; D J Loskutoff; Carlos F Barbas
Functional display of human plasminogen-activator inhibitor 1 (PAI-1) on phages: novel perspectives for structure-function analysis by error-prone DNA synthesis.
Gene 1993;128(1):135-40.
1993: R K Gebbink; C H Reynolds; Douglas M Tollefsen; K Mertens; Hans Pannekoek
Specific glycosaminoglycans support the inhibition of thrombin by plasminogen activator inhibitor 1.
Biochemistry 1993;32(6):1675-80.
1993: Jan Voorberg; R Fontijn; Jero Calafat; Hans Janssen; Jan A van Mourik; Hans Pannekoek
Biogenesis of von Willebrand factor-containing organelles in heterologous transfected CV-1 cells.
The EMBO journal 1993;12(2):749-58.
1993: Anton J G Horrevoets; Guido Tans; Age K Smilde; Anton-Jan van Zonneveld; Hans Pannekoek
Thrombin-variable region 1 (VR1). Evidence for the dominant contribution of VR1 of serine proteases to their interaction with plasminogen activator inhibitor 1.
The Journal of biological chemistry 1993;268(2):779-82.
1992: Anne-Sophie Ribba; Jan Voorberg; D Meyer; Hans Pannekoek; G Pietu
Characterization of recombinant von Willebrand factor corresponding to mutations in type IIA and type IIB von Willebrand disease.
The Journal of biological chemistry 1992;267(32):23209-15.
1992: C Kost; W Stüber; H J Ehrlich; Hans Pannekoek; Klaus T Preissner
Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
The Journal of biological chemistry 1992;267(17):12098-105.
1992: H J Ehrlich; R K Gebbink; J Keijer; Hans Pannekoek
Elucidation of structural requirements on plasminogen activator inhibitor 1 for binding to heparin.
The Journal of biological chemistry 1992;267(16):11606-11.
1992: Marcel Levi; Bart J Biemond; Anton-Jan van Zonneveld; JW ten Cate; Hans Pannekoek
Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis.
Circulation 1992;85(1):305-12.
1991: H J Ehrlich; R K Gebbink; Klaus T Preissner; J Keijer; N L Esmon; K Mertens; Hans Pannekoek
Thrombin neutralizes plasminogen activator inhibitor 1 (PAI-1) that is complexed with vitronectin in the endothelial cell matrix.
The Journal of cell biology 1991;115(6):1773-81.
1991: J Keijer; M Linders; J J Wegman; H J Ehrlich; K Mertens; Hans Pannekoek
On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
Blood 1991;78(5):1254-61.
1991: J Keijer; M Linders; Anton-Jan van Zonneveld; H J Ehrlich; J P de Boer; Hans Pannekoek
The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: localization of interaction sites and physiologic relevance.
Blood 1991;78(2):401-9.
1991: J Keijer; H J Ehrlich; M Linders; Klaus T Preissner; Hans Pannekoek
Vitronectin governs the interaction between plasminogen activator inhibitor 1 and tissue-type plasminogen activator.
The Journal of biological chemistry 1991;266(16):10700-7.
1991: Jan Voorberg; R Fontijn; Jero Calafat; Hans Janssen; Jan A van Mourik; Hans Pannekoek
Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids.
The Journal of cell biology 1991;113(1):195-205.
1991: C de Vries; H Veerman; M E Nesheim; Hans Pannekoek
Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
Thrombosis and haemostasis 1991;65(3):280-5.
1991: A Leyte; Jan Voorberg; H B Van Schijndel; B Duim; Hans Pannekoek; Jan A van Mourik
The pro-polypeptide of von Willebrand factor is required for the formation of a functional factor VIII-binding site on mature von Willebrand factor.
The Biochemical journal 1991;274 ( Pt 1)():257-61.
1991: H J Ehrlich; J Keijer; Klaus T Preissner; R K Gebbink; Hans Pannekoek
Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin.
Biochemistry 1991;30(4):1021-8.
1990: Hans Pannekoek; H R Lijnen; D J Loskutoff
Recommendations for the nomenclature of mutant fibrinolytic genes and their proteins. Report of the SSC Fibrinolysis Subcommittee 1990.
Thrombosis and haemostasis 1990;64(4):600-3.
1990: Klaus T Preissner; J Grulich-Henn; H J Ehrlich; P Declerck; C Justus; D Collen; Hans Pannekoek; G Müller-Berghaus
Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin.
The Journal of biological chemistry 1990;265(30):18490-8.
1990: C de Vries; H Veerman; E Koornneef; Hans Pannekoek
Tissue-type plasminogen activator and its substrate Glu-plasminogen share common binding sites in limited plasmin-digested fibrin.
The Journal of biological chemistry 1990;265(23):13547-52.
1990: H J Ehrlich; R K Gebbink; J Keijer; M Linders; Klaus T Preissner; Hans Pannekoek
Alteration of serpin specificity by a protein cofactor. Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties.
The Journal of biological chemistry 1990;265(22):13029-35.
1990: Jan Voorberg; R Fontijn; Jan A van Mourik; Hans Pannekoek
Domains involved in multimer assembly of von willebrand factor (vWF): multimerization is independent of dimerization.
The EMBO journal 1990;9(3):797-803.
1989: A Leyte; Koen Mertens; B Distel; R F Evers; M J De Keyzer-Nellen; M M Groenen-Van Dooren; J De Bruin; Hans Pannekoek; Jan A van Mourik; M P Verbeet
Inhibition of human coagulation factor VIII by monoclonal antibodies. Mapping of functional epitopes with the use of recombinant factor VIII fragments.
The Biochemical journal 1989;263(1):187-94.
1989: R J Aerts; K Gillis; Hans Pannekoek
Single-chain and two-chain tissue-type plasminogen activator (t-PA) bind differently to cultured human endothelial cells.
Thrombosis and haemostasis 1989;62(2):699-703.
1989: O F Wagner; C de Vries; C Hohmann; H Veerman; Hans Pannekoek
Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
The Journal of clinical investigation 1989;84(2):647-55.
1989: C de Vries; H Veerman; Hans Pannekoek
Identification of the domains of tissue-type plasminogen activator involved in the augmented binding to fibrin after limited digestion with plasmin.
The Journal of biological chemistry 1989;264(21):12604-10.
1988: C L Verweij; M Hart; Hans Pannekoek
Proteolytic cleavage of the precursor of von Willebrand factor is not essential for multimer formation.
The Journal of biological chemistry 1988;263(17):7921-4.
1988: C de Vries; H Veerman; F Blasi; Hans Pannekoek
Artificial exon shuffling between tissue-type plasminogen activator (t-PA) and urokinase (u-PA): a comparative study on the fibrinolytic properties of t-PA/u-PA hybrid proteins.
Biochemistry 1988;27(7):2565-72.
1988: C L Verweij; R Quadt; E Briët; K Dubbeldam; G B van Ommen; Hans Pannekoek
Genetic linkage of two intragenic restriction fragment length polymorphisms with von Willebrand's disease type IIA. Evidence for a defect in the von Willebrand factor gene.
The Journal of clinical investigation 1988;81(4):1116-21.
1987: Hans Lambers; M Cammenga; B W König; Koen Mertens; Hans Pannekoek; Jan A van Mourik
Activation of human endothelial cell-type plasminogen activator inhibitor (PAI-1) by negatively charged phospholipids.
The Journal of biological chemistry 1987;262(36):17492-6.
1987: J P Brakenhoff; Els R de Groot; R F Evers; Hans Pannekoek; Lucien A Aarden
Molecular cloning and expression of hybridoma growth factor in Escherichia coli.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(12):4116-21.
1987: C L Verweij; M Hart; Hans Pannekoek
Expression of variant von Willebrand factor (vWF) cDNA in heterologous cells: requirement of the pro-polypeptide in vWF multimer formation.
The EMBO journal 1987;6(10):2885-90.
1987: D J Loskutoff; M Linders; J Keijer; H Veerman; Harm van Heerikhuizen; Hans Pannekoek
Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns.
Biochemistry 1987;26(13):3763-8.
1987: Anton-Jan van Zonneveld; H Veerman; J P Brakenhoff; L A Aarden; J F Cajot; Hans Pannekoek
Mapping of epitopes on human tissue-type plasminogen activator with recombinant deletion mutant proteins.
Thrombosis and haemostasis 1987;57(1):82-6.
1986: Anton-Jan van Zonneveld; H Veerman; Hans Pannekoek
On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon-amino caproic acid.
The Journal of biological chemistry 1986;261(30):14214-8.
1986: Hans Pannekoek; H Veerman; Hans Lambers; P Diergaarde; C L Verweij; Anton-Jan van Zonneveld; Jan A van Mourik
Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family.
The EMBO journal 1986;5(10):2539-44.
1986: Anton-Jan van Zonneveld; H Veerman; Hans Pannekoek
Autonomous functions of structural domains on human tissue-type plasminogen activator.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(13):4670-4.
1986: Anton-Jan van Zonneveld; H Veerman; M E MacDonald; Jan A van Mourik; Hans Pannekoek
Structure and function of human tissue-type plasminogen activator (t-PA).
Journal of cellular biochemistry 1986;32(3):169-78.